Spyre Therapeutics, Inc. (SYRE) Q3 2025 10-Q Quarterly Report
Spyre Therapeutics, Inc. (SYRE) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Spyre Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New material weakness in internal controls discovered Q4 2024 led to restatements of prior net loss per share disclosures
- • Going concern risk heightened by potential difficulty raising capital amid macroeconomic volatility and intensified biotech funding competition
- • FDA and other government agency disruptions, including potential shutdowns, may delay clinical trial review and product approvals
- • Intense competition from larger biopharma firms and emerging companies threatens clinical trial recruitment and future market penetration
- • Cash, cash equivalents, and marketable securities totaled $486.2 million as of September 30, 2025, with ongoing capital needs to fund operations
Spyre Therapeutics, Inc. Q3 2025 Quarterly FinancialsXBRL
Net Income
-$11M
▲ +83.8% YoY▲ +69.5% QoQ
ROE
-2.5%
Total Assets
$505M
EPS (Diluted)
$-0.15
▲ +89.4% YoY▲ +86.2% QoQ
Operating Cash Flow
-$37M
▼ -26.2% YoY▲ +20.3% QoQ
Source: XBRL data from Spyre Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Spyre Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.